Wednesday, 18 December 2013

ISCO Liver program receives award

International Stem Cell Corporation (ISCO), a California-based biotechnology company developing stem cell based therapies, announced today that it was awarded the Presidential Poster of Distinction by the American Association for the Study of Liver Disease (AASLD) at the 64th Annual Liver Meeting in Washington, D.C.

The data reported in this pre-clinical study showed that transplantation of hpSC-derived hepatocytes cells (HLCs) elicits a significant decrease and long-term stabilization of bilirubin levels in the serum of Gunn rats, a well-established animal model of Crigler-Najjar syndrome type 1 (CN1), an inborn error of bilirubin metabolism. Moreover, at four months following treatment no adverse safety signals were detected.

CN1 is a rare inherited liver-based metabolic disorder in which the host liver lacks one hepatic enzyme, UGT1A1, essential for the conjugation and excretion of the toxin bilirubin. This pre-clinical study provides important supportive evidence of the potential safety and efficacy of HLCs which could constitute a reliable source for large numbers of transplantable cells. In the long-term, experience with HLC transplantation for CN1 could potentially be used to develop therapeutic strategies for more common inherited liver diseases.
"Being awarded such a prestigious honor is a testament to the quality of our scientific team at ISCO The data presented at this conference demonstrates the unique nature of our HLCs and their potential efficacy in a clinical setting." said Ruslan Semechkin, Ph.D., Chief Scientific Officer of ISCO. 


No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !